ReviewBioprocess and biosystems engineering2025
Current strategies for rutin nano-formulation; a promising bioactive compound with increased efficacy.
Review in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comparative evaluation of quercetin, rutin, and their nanoparticles: enhanced antimicrobial and antioxidant activities.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Fabrication of Multifunctional Films Incorporating Purple Sweet Potato Anthocyanins and ZIF-8-NHPolymers · 2026Article
- Evaluation of the efficacy of rutin, rutin nanocrystals, and rutin spanlastics nanoparticles as antitumor and antioxidant drug delivery systems.Discover nano · 2026Article
- Rutin as a Potential Therapeutic Agent for Multi-Organ Ischemia-Reperfusion Injury: From Multidimensional Mechanisms to Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Molecular mechanisms of neuroprotective effect of rutin.Frontiers in pharmacology · 2025Review
- The potential role of rutin, a flavonoid, in the management of cancer through modulation of cell signaling pathways.Open life sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rutin is an herbal polyphenolic compound recognized for its numerous therapeutic benefits, including antioxidant, anticancer, and antimicrobial properties. However, its application in biomedical fields encounters significant challenges, such as low solubility, poor absorption, low bioavailability, short half-life, and rapid metabolism. In recent years, advancements in nanotechnology have presented promising solutions to these limitations. Consequently, various nano-formulation strategies have been developed to enhance rutin's solubility, absorption, and overall efficacy. These strategies can be broadly categorized into two approaches. The first involves transforming rutin into nanocrystals without the use of any secondary compounds. The second approach entails nano-formulating rutin with other compounds, including proteins, polysaccharides, lipids, polymers, and metals. This study offers a review of these approaches and their applications in biomedical sciences, focusing on their categories, preparation methods, and biomedical properties. Initially, the pharmacological potential of rutin, its application in recent clinical trials, and its mechanisms of action are outlined. Next, it explores how nano-carriers can enhance rutin's bioavailability. Subsequently, the types of nanostructures employed are categorized, along with a discussion of their fabrication methods and benefits. In some instances, certain drawbacks are also reported. The data provided can guide the selection of optimal strategies for rutin nano-formulation, based on the intended biomedical application.
Indexed as
Identifiers
40148481What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.